You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hematologic Malignancies, venetoclax

Showing 1 - 25 of 4,490
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Non-Hodgkin Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Vysis LSI MYC Break Apart Rearrangement

Recruiting
  • Lymphoma
  • +4 more
  • Vysis LSI MYC Break Apart Rearrangement Probe Kit
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Relapsed or Refractory Hematologic Malignancies Trial in Chicago (Omacetaxine, Venetoclax)

Recruiting
  • Relapsed or Refractory Hematologic Malignancies
  • Chicago, Illinois
    University of Illinois Cancer Center
Sep 27, 2022

Venetoclax Tablets Crushed and Dissolved Into a Solution

Not yet recruiting
  • Hematologic Malignancy
  • +18 more
  • 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
Nov 8, 2023

MDS, de Novo, MDS, Secondary, MDS, Previously Treated Trial in Boston (Venetoclax, Azacitidine, Cytarabine)

Recruiting
  • Myelodysplastic Syndromes, de Novo
  • +10 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 23, 2023

Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +4 more
  • Utrecht, Netherlands
    Princess Máxima Center for Pediatric Oncology
Feb 22, 2023

Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +4 more
  • Utrecht, Netherlands
    Princess Máxima Center for Pediatric Oncology
Feb 16, 2023

Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • +4 more
  • Utrecht, Netherlands
    Princess Máxima Center for Pediatric Oncology
Feb 20, 2023

Hematologic Malignancy, Older Patients, Allogeneic Hematopoietic Stem Cell Transplantation Trial in Hangzhou, Ningbo, Wenzhou

Recruiting
  • Hematologic Malignancy
  • +2 more
  • venetoclax combining with fludarabine and melphalan
  • Hangzhou, Zhejiang, China
  • +7 more
Oct 20, 2021

Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Tumor, Myelodysplastic Syndrome Trial in United States (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia
  • +5 more
  • Boston, Massachusetts
  • +3 more
Jun 30, 2021

Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma Trial in Australia, Germany, United States

Terminated
  • Acute Myeloid Leukemia
  • +2 more
  • Duarte, California
  • +16 more
Dec 3, 2021

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia Trial in Los Angeles, Sacramento, Oklahoma City (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia
  • Recurrent Acute Myeloid Leukemia
  • Los Angeles, California
  • +2 more
Mar 11, 2022

Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma Trial in Worldwide (CCS1477, Pomalidomide,

Recruiting
  • Haematological Malignancy
  • +4 more
  • Phoenix, Arizona
  • +14 more
Aug 22, 2022

Acute Myeloid Leukemia (AML) Trial in United States (Alvocidib (flavopiridol) and cytarabine (Ara-C), Alvocidib (flavopiridol))

Terminated
Has Results
  • Acute Myeloid Leukemia (AML)
  • Alvocidib (flavopiridol) and cytarabine (Ara-C)
  • Alvocidib (flavopiridol)
  • Clovis, California
  • +17 more
Sep 22, 2022

Hypomethylating Agent, Venetoclax, Myeloid Malignancy Trial in Shanghai (Venetoclax, Azacitidine or decitabine)

Recruiting
  • Hypomethylating Agent
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Jiao Tong University School of Medicine Affilated Shang
May 2, 2023

Relmacabtagene Autoleucel in Hematologic Malignancies

Not yet recruiting
  • Lymphoma, B-Cell
  • +2 more
  • Relmacabtagene Autoleucel
  • Beijing, Beijing, China
  • +1 more
Nov 15, 2023

Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL) Trial in Japan (azacitadine, venetoclax,

Completed
  • Non-Hodgkin Lymphoma (NHL)
  • +4 more
  • Nagoya shi, Aichi, Japan
  • +13 more
Jul 29, 2021

Myeloid Malignancy, MDS, Myelofibrosis Trial in Boston (Navitoclax, Venetoclax, Decitabine)

Recruiting
  • Myeloid Malignancy
  • +4 more
  • Boston, Massachusetts
  • +2 more
Jul 21, 2022

Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome Trial (VIP943)

Not yet recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • (no location specified)
Sep 5, 2023

Hematologic Malignancies Trial in Zhengzhou (RD13-02 cell infusion)

Recruiting
  • Hematologic Malignancies
  • RD13-02 cell infusion
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jun 26, 2023

Leukemia, Myeloid, Acute, MDS, Hematopoietic Stem Cell Transplantation Trial in Shanghai (Venetoclax plus RIC)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • +3 more
  • Venetoclax plus RIC
  • Shanghai, Shanghai, China
    Shanghai General Hospital
Oct 12, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial (Routine care as per

Not yet recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +5 more
  • Routine care as per site standard.
  • (no location specified)
Sep 15, 2023

Hematologic Malignancies Trial in Assiut (CD56)

Recruiting
  • Hematologic Malignancies
  • CD56
  • Assiut, Egypt
  • +1 more
Jul 20, 2022

Hematologic Tumors, Neutropenia, Anemia Trial in Wuhan (umbilical cord derived mesenchymal stem cells)

Not yet recruiting
  • Hematologic Neoplasms
  • +5 more
  • umbilical cord derived mesenchymal stem cells
  • Wuhan, Hubei, China
  • +2 more
Jan 3, 2023

Hematologic Malignancy, Hematologic Tumors, Hematologic Diseases Trial in Nanjing, Suzhou, Tianjin (Flow Cytometry)

Not yet recruiting
  • Hematologic Malignancy
  • +2 more
  • Flow Cytometry
  • Nanjing, Jiangsu, China
  • +2 more
Apr 17, 2023